These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Cutaneous alterations in vasculitides : Part 2: Special aspects of diseases of large, medium and small vessels]. Sunderkötter C; Michl C Internist (Berl); 2019 Aug; 60(8):805-813. PubMed ID: 31300830 [TBL] [Abstract][Full Text] [Related]
7. Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis. Simon A; Subra JF; Guilpain P; Jeannin P; Pignon P; Blanchard S; Garo E; Jaillon S; Chevailler A; Renier G; Puéchal X; Bottazzi B; Mantovani A; Delneste Y; Augusto JF PLoS One; 2016; 11(1):e0147091. PubMed ID: 26797217 [TBL] [Abstract][Full Text] [Related]
8. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Fazzini F; Peri G; Doni A; Dell'Antonio G; Dal Cin E; Bozzolo E; D'Auria F; Praderio L; Ciboddo G; Sabbadini MG; Manfredi AA; Mantovani A; Querini PR Arthritis Rheum; 2001 Dec; 44(12):2841-50. PubMed ID: 11762945 [TBL] [Abstract][Full Text] [Related]
9. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Dagna L; Salvo F; Tiraboschi M; Bozzolo EP; Franchini S; Doglioni C; Manfredi AA; Baldissera E; Sabbadini MG Ann Intern Med; 2011 Oct; 155(7):425-33. PubMed ID: 21969341 [TBL] [Abstract][Full Text] [Related]
10. Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited. Keser G; Aksu K; Direskeneli H Rheumatology (Oxford); 2018 May; 57(5):784-790. PubMed ID: 28968895 [TBL] [Abstract][Full Text] [Related]
11. The pathology of large-vessel vasculitides. Miller DV; Maleszewski JJ Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S92-8. PubMed ID: 21586202 [TBL] [Abstract][Full Text] [Related]
12. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus. Cieślik P; Hrycek A Autoimmunity; 2015 Jun; 48(4):242-50. PubMed ID: 25401491 [TBL] [Abstract][Full Text] [Related]
13. The modern therapy of systemic vasculitides: perspectives and challenges. Novikov PI; Zykova AS; Moiseev SV Ter Arkh; 2018 Feb; 90(1):76-85. PubMed ID: 30701763 [TBL] [Abstract][Full Text] [Related]
15. Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus. Sahin S; Adrovic A; Barut K; Durmus S; Gelisgen R; Uzun H; Kasapcopur O Lupus; 2017 Sep; 26(10):1089-1094. PubMed ID: 28420068 [TBL] [Abstract][Full Text] [Related]
16. Progranulin antibodies in autoimmune diseases. Thurner L; Preuss KD; Fadle N; Regitz E; Klemm P; Zaks M; Kemele M; Hasenfus A; Csernok E; Gross WL; Pasquali JL; Martin T; Bohle RM; Pfreundschuh M J Autoimmun; 2013 May; 42():29-38. PubMed ID: 23149338 [TBL] [Abstract][Full Text] [Related]
17. Neurological complications of connective tissue and other "collagen-vascular" diseases. Cohen SB; Hurd ER Semin Arthritis Rheum; 1981 Aug; 11(1):190-212. PubMed ID: 6116280 [TBL] [Abstract][Full Text] [Related]
18. Thrombo-embolic and vascular complications in vasculitis syndromes. Somer T Eur Heart J; 1993 Dec; 14 Suppl K():24-9. PubMed ID: 7907547 [TBL] [Abstract][Full Text] [Related]
19. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Schmidt WA; Blockmans D Curr Opin Rheumatol; 2005 Jan; 17(1):9-15. PubMed ID: 15604899 [TBL] [Abstract][Full Text] [Related]
20. Prognosis and future developments in vasculitis. Basu N; Karabayas M; Pusey C Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):148-165. PubMed ID: 30526894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]